Literature DB >> 8196083

Efficacy of mammographic screening of the elderly: a case-referent study in the Nijmegen program in The Netherlands.

J A van Dijck1, R Holland, A L Verbeek, J H Hendriks, M Mravunac.   

Abstract

BACKGROUND: Only a few small studies have been conducted to examine the usefulness of mammographic screening in elderly women. These studies suggest that the screening-related reduction in breast cancer mortality rates is less than the estimated 20%-40% reduction observed for women aged 50-70 years at the time of their first screening.
PURPOSE: We have studied the efficacy of continued mammographic screening for breast cancer of elderly women within our screening program.
METHODS: In 1975, a breast cancer screening program was started in the city of Nijmegen. The Netherlands. During each biennial screening round, approximately 30,000 women aged 40 years and older were personally invited to participate. Single-view mammography was administered. The present study was conducted using a case-referent design. In order to be eligible for inclusion in this study, women had to have been invited to participate in the mammography screening program at least twice, with the most recent invitation having occurred when each woman was 65 years or older. The cases studied comprised 33 women in this group who had died of breast cancer at some point during 1977 through 1988. Referents were matched for age at last invitation to screening prior to the diagnosis of breast cancer and for the number of previous invitations to screenings. Five referents were randomly selected for each case. Breast cancer mortality rate ratios (RR) were calculated for several categories of attendance to the screening.
RESULTS: The RR of those who attended the last screening versus those who failed to do so was 0.58 (95% confidence interval [CI] = 0.24-1.41); for women aged 65-74, the RR was 0.34 (95% CI = 0.12-0.97) and for women aged 75 or over, 2.87 (95% CI = 0.62-13.2). The RR of those who attended the screening before and after the age of 65, relative to those who attended before 65 only, was 0.26 (95% CI = 0.05-1.32).
CONCLUSION: Although self-selection bias was present in our data, it was not likely to be responsible for the beneficial effect in women aged 65-74 at the time of invitation to screenings. It probably was responsible for the reversed RR (RR > 1) in the group of women 75 years and older. IMPLICATION: Continuation of mammographic screening until at least the age of 75 years may lead to a reduction of breast cancer mortality among elderly women.

Entities:  

Mesh:

Year:  1994        PMID: 8196083     DOI: 10.1093/jnci/86.12.934

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  4 in total

1.  Long term breast cancer screening in Nijmegen, The Netherlands: the nine rounds from 1975-92.

Authors:  J D Otten; J A van Dijck; P G Peer; H Straatman; A L Verbeek; M Mravunac; J H Hendriks; R Holland
Journal:  J Epidemiol Community Health       Date:  1996-06       Impact factor: 3.710

Review 2.  Mammographic screening in older women. Is it worthwhile?

Authors:  J A van Dijck; M J Broeders; A L Verbeek
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

3.  Mammographic screening after the age of 65 years: early outcomes in the Nijmegen programme.

Authors:  J van Dijck; A Verbeek; J Hendriks; R Holland; M Mravunac
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

4.  Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA.

Authors:  Felipe Ades; Christelle Senterre; Dimitrios Zardavas; Evandro de Azambuja; Razvan Popescu; Martine Piccart
Journal:  PLoS One       Date:  2017-03-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.